WallStSmart

Insight Molecular Diagnostics Inc. (IMDX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 2774511% more annual revenue ($46.34B vs $1.67M). TMO leads profitability with a 15.0% profit margin vs 0.0%. TMO earns a higher WallStSmart Score of 60/100 (C+).

IMDX

Avoid

17

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -27.90

TMO

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IMDX.

TMOSignificantly Overvalued (-76.7%)

Margin of Safety

-76.7%

Fair Value

$345.06

Current Price

$609.82

$264.76 premium

UndervaluedFair: $345.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMDX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1210/10

Conservative balance sheet, low leverage

TMO2 strengths · Avg: 9.0/10
Market CapQuality
$225.48B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

IMDX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$131.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.804/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IMDX

The strongest argument for IMDX centers on Debt/Equity.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : IMDX

The primary concerns for IMDX are EPS Growth, Market Cap, Profit Margin.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

IMDX carries more volatility with a beta of 1.82 — expect wider price swings.

TMO is growing revenue faster at 10.5% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TMO scores higher overall (60/100 vs 17/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insight Molecular Diagnostics Inc.

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?